Drug Discovery for Kinetoplastid Diseases: Future Directions - Archive ouverte HAL Access content directly
Journal Articles ACS Infectious Diseases Year : 2018

Drug Discovery for Kinetoplastid Diseases: Future Directions

(1) , (2) , (3) , (3) , (4) , (5) , (1) , (6) , , (7) , (8, 9) , (10) , (11) , (12) , (13) , (14) , (15) , (1) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Glenn Dranoff
  • Function : Author
  • PersonId : 924474
Janis K. Lazdins-Helds
  • Function : Author
Gerald F Späth

Abstract

Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
Fichier principal
Vignette du fichier
acsinfecdis.8b00298.pdf (1.03 Mo) Télécharger le fichier
Loading...

Dates and versions

pasteur-01974311 , version 1 (08-01-2019)

Licence

Attribution - NonCommercial - ShareAlike - CC BY 4.0

Identifiers

Cite

Srinivasa Rao, Michael Barrett, Glenn Dranoff, Christopher J. Faraday, Claudio R. Gimpelewicz, et al.. Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2018, ⟨10.1021/acsinfecdis.8b00298⟩. ⟨pasteur-01974311⟩

Collections

PASTEUR RIIP
105 View
101 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More